, India
3 views

Incentives to boost India's local raw pharma materials output

The country is looking to ease its dependency on China for raw material imports.

India’s government has approved a production-linked incentive (PLI) scheme targeting India’s pharma sector for enhancing drug manufacturing capabilities and expanding exports, which will help boost local output of key raw pharma materials in India, according to Fitch Solutions.

The objective of the scheme is to enhance the country’s manufacturing capabilities by ramping up investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector.

“India aims to attract greater investments from global and domestic players in its pharmaceuticals sector, which is mostly known for its low-value generic drugs production,” the report stated.

Another objective of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting-edge technology and thereby penetrate the global value chains, the statement said.

In addition, after the experience of the pandemic, India is keen to secure its drugs market from external shocks, lessen import dependencies, and continue support for the domestic production capabilities in active pharmaceutical ingredients (APIs), key starting materials (KSMs), and drug intermediates (DIs).

By far, a total of 19 companies have been approved as PLI beneficiaries for the promotion of domestic manufacturing of critical KSMs/DIs/APIs and have committed to investments worth $633.76m (INR46.23b).

According to official sources, commercial production will begin by 1 April 2023 and the PLI scheme will be carried over a period of six years, and the disbursal of production-linked incentives by the government will be up to a maximum of $667.62m (INR48.7b).

Fitch noted that pharmaceutical raw materials accounted for over half of pharma imports in India in 2019, of which 70% were from China largely because of lower costs. For some drugs, such as paracetamol and ibuprofen, the dependence on China is almost 100%.

India’s imports of pharmaceutical products from China, rose to $150m (INR11.5b) in 2019-2020 from $120m (INR9.4b) in 2015-2016, a cumulative growth of 28%, according to data from the commerce ministry. Including APIs, chemicals and key starting materials, India’s imports from China are estimated to be about $2b (INR152.5b) a year.

“Therefore, this overdependence poses a major risk of severe drug shortage and has a direct bearing on the drug security of the country,” the report stated.

However, reducing dependence on China will be a challenge. Fitch noted that any decoupling from China must be strategic and with significant policy support. Furthermore, it will take time for a paced indigenisation.

“Nevertheless, developing domestic capabilities in the medium to long term and reducing dependence on China would be strategically prudent,” the report added.
 

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox

Find out who won at this year's Healthcare Asia Awards and Healthcare Asia Pharma Awards 

The event was held via video conferencing that started last 15 April.

What investment opportunities await for India’s health-tech space?

Before the pandemic, the industry focussed on wearables, lifestyle-linked problems, and more.

Singapore’s Tan Tock Seng Hospital closes wards to visitors

Two patients and two staff were infected by COVID-19.

Hygeia Healthcare buys 100% stake in Etern Group for $268m

The acquisition indirectly holds 98% of Suzhou Yongding Hospital in Jiangsu.

How reach52 bridges the gap in healthcare with tech

The unique startup aims to connect to 250 million individuals across the globe by 2030.

He Health bags internet hospital license in China

The online platform offers services such as men’s health consultations.

Indonesia's telehealth platform Halodoc bags $80m in funding

The funds will be used to deepen its penetration in key healthcare verticals in Indonesia.

South Korea eases requirements for drug imports

Pharmaceutical companies could benefit from the government’s drive to reduce regulatory uncertainty.

Taiwan's novel pharma products hit by low reimbursement prices

The low rates are discouraging the launch of new innovative products, insiders say.

Japan's liver cancer surveillance program hailed as world's best

The country established the programme for early detection of HCC in the 1980s.